CRIS vs CLYM

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Sep 29, 2026

CRIS

38.8
AI Score
VS
CLYM Wins

CLYM

45.4
AI Score

Investment Advisor Scores

CRIS

39score
Recommendation
SELL

CLYM

45score
Recommendation
HOLD

AI Analyst Insights

AI insights temporarily unavailable

Detailed Metrics Comparison

Metric CRIS CLYM Winner
Net Income -7.58M -27.22M CRIS
Operating Income -5.71M -30.57M CRIS
ROE -138.8% -11.4% CLYM
ROA -38.0% -11.1% CLYM
Total Assets 19.97M 246.29M CLYM
Cash 5.06M 44.11M CLYM
Current Ratio 0.49 31.45 CLYM

Relative Price Performance (Last 90 Days)

CRIS 1M: -41.8% · 3M: -86.5% CLYM 1M: -27.3% · 3M: -17.6%

Current Technical Phase

CRIS

Markdown
Sell / avoid

Price below a falling SMA50 (slope -32.4%), weak momentum, RSI 23

RSI (14): 23.0 · Price: $0.80

CLYM

Neutral
Hold

Mixed signals - no dominant trend phase, RSI 30

RSI (14): 30.3 · Price: $10.94

Fundamentals Snapshot

Metric CRIS CLYM
Market Cap — —
Forward P/E -0.1 -10.9
Trailing P/E 0.2 —
Revenue (TTM) — —
Revenue Growth -0.7% 0.0%
Gross Margin -4.9% —
Operating Margin -8.3% 0.0%
EPS 3.65 -0.79
Dividend Yield — —

Frequently Asked Questions

Based on our detailed analysis, CLYM is currently the stronger investment candidate, winning 5 of the key financial metrics based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.